Enapotamab vedotin

DB16156Investigational

Enapotamab vedotin is under investigation in clinical trial NCT02988817 (Enapotamab Vedotin (Humax-axl-adc) Safety Study in Patients With Solid Tumors).

Mechanism: Pharmacologically active on Tyrosine-protein kinase receptor UFO
Curator reviewed
Also known as: Humax axl adc · HuMax-AXL-ADC · Immunoglobulin g1, anti-(human growth factor receptor axl)(human humax-axl .gamma.1-chain), disulfide with human humax-axl .kappa.-chain, dimer tetrakis(thioether) with vedotin
Code names: AXL-107-MMAE

Resolves to

Compound

UNII43HH4XYH2NCAS1912424-97-5

Targets

P30530AXL

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Enapotamab vedotin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account